BACKGROUND: Dimebolin (latrepirdine), a compound with multiple potential drug targets, is being evaluated in clinical trials for the treatment of Alzheimer's disease (AD) and preliminary results suggest it can slow the disease process. There is also evidence that dimebolin directly improves aspects of cognition. Here we examined the acute effect of dimebolin on components of working memory in non-human primates, young adult (11-17 years old) and aged (20-31 years old) rhesus macaques. EXPERIMENTAL APPROACH: The effects of dimebolin (3.9-118 µg kg(-1)) on working memory, as measured by performance on delayed matching-to-sample (DMTS), were examined in the normal young adult monkeys and aged adult monkeys. All the monkeys studied were proficient in the performance of a computer-assisted DMTS task. In a subsequent experiment in the same subjects, dimebolin was administered 15 min before a cognitively-impairing dose (20 µg kg(-1)) of scopolamine. KEY RESULTS: In both the young adult and aged monkeys, dimebolin significantly increased the DMTS task accuracies. In young adults, the task improvement was associated with long (retention/retrieval) delay trials, and a protracted enhancement was observed for sessions run 24 h post administration of a single dose. Dimebolin did not significantly attenuate the scopolamine-induced impairment. In the aged monkeys, dimebolin significantly improved the reduced task accuracies associated with long delay intervals. CONCLUSIONS AND IMPLICATIONS: Here we demonstrated that dimebolin is able to improve components of working memory in monkeys and to induce a protracted response for at least 24 h after administration of a single dose.
BACKGROUND:Dimebolin (latrepirdine), a compound with multiple potential drug targets, is being evaluated in clinical trials for the treatment of Alzheimer's disease (AD) and preliminary results suggest it can slow the disease process. There is also evidence that dimebolin directly improves aspects of cognition. Here we examined the acute effect of dimebolin on components of working memory in non-human primates, young adult (11-17 years old) and aged (20-31 years old) rhesus macaques. EXPERIMENTAL APPROACH: The effects of dimebolin (3.9-118 µg kg(-1)) on working memory, as measured by performance on delayed matching-to-sample (DMTS), were examined in the normal young adult monkeys and aged adult monkeys. All the monkeys studied were proficient in the performance of a computer-assisted DMTS task. In a subsequent experiment in the same subjects, dimebolin was administered 15 min before a cognitively-impairing dose (20 µg kg(-1)) of scopolamine. KEY RESULTS: In both the young adult and aged monkeys, dimebolin significantly increased the DMTS task accuracies. In young adults, the task improvement was associated with long (retention/retrieval) delay trials, and a protracted enhancement was observed for sessions run 24 h post administration of a single dose. Dimebolin did not significantly attenuate the scopolamine-induced impairment. In the aged monkeys, dimebolin significantly improved the reduced task accuracies associated with long delay intervals. CONCLUSIONS AND IMPLICATIONS: Here we demonstrated that dimebolin is able to improve components of working memory in monkeys and to induce a protracted response for at least 24 h after administration of a single dose.
Authors: N N Lermontova; A E Redkozubov; E F Shevtsova; T P Serkova; E G Kireeva; S O Bachurin Journal: Bull Exp Biol Med Date: 2001-11 Impact factor: 0.804
Authors: Marco Giorgetti; Jacqueline A Gibbons; Sebastián Bernales; Iván E Alfaro; Christophe Drieu La Rochelle; Thomas Cremers; C Anthony Altar; Robert Wronski; Birgit Hutter-Paier; Andrew A Protter Journal: J Pharmacol Exp Ther Date: 2010-03-01 Impact factor: 4.030
Authors: Sergey O Bachurin; Elena P Shevtsova; Elena G Kireeva; Gregory F Oxenkrug; Sergey O Sablin Journal: Ann N Y Acad Sci Date: 2003-05 Impact factor: 5.691
Authors: Hervé Schaffhauser; Joanne R Mathiasen; Amy Dicamillo; Mark J Huffman; Lily D Lu; Beth A McKenna; Jie Qian; Michael J Marino Journal: Biochem Pharmacol Date: 2009-06-21 Impact factor: 5.858
Authors: Thelma R Cowley; Rodrigo Esteban González-Reyes; Jill C Richardson; David Virley; Neil Upton; Marina A Lynch Journal: Neurochem Res Date: 2012-09-26 Impact factor: 3.996
Authors: Prashant R Bharadwaj; Giuseppe Verdile; Renae K Barr; Veer Gupta; John W Steele; M Lenard Lachenmayer; Zhenyu Yue; Michelle E Ehrlich; Gregory Petsko; Shulin Ju; Dagmar Ringe; Sonia E Sankovich; Joanne M Caine; Ian G Macreadie; Sam Gandy; Ralph N Martins Journal: J Alzheimers Dis Date: 2012 Impact factor: 4.472
Authors: Sylvia E Perez; Muhammad Nadeem; Katherine R Sadleir; Joanna Matras; Christy M Kelley; Scott E Counts; Robert Vassar; Elliott J Mufson Journal: Int J Physiol Pathophysiol Pharmacol Date: 2012-09-20
Authors: Sergey O Bachurin; Tatyana A Shelkovnikova; Alexey A Ustyugov; Owen Peters; Ina Khritankova; Marina A Afanasieva; Tatyana V Tarasova; Igor I Alentov; Vladimir L Buchman; Natalia N Ninkina Journal: Neurotox Res Date: 2011-12-17 Impact factor: 3.911
Authors: P Weisová; S P Alvarez; S M Kilbride; U Anilkumar; B Baumann; J Jordán; T Bernas; H J Huber; H Düssmann; J H M Prehn Journal: Transl Psychiatry Date: 2013-10-22 Impact factor: 6.222
Authors: P R Bharadwaj; K A Bates; T Porter; E Teimouri; G Perry; J W Steele; S Gandy; D Groth; R N Martins; Giuseppe Verdile Journal: Transl Psychiatry Date: 2013-12-03 Impact factor: 6.222